Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens

NCT05871489 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

800

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis, Multidrug-Resistant
HIV

Interventions

DRUG: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
DRUG: Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)
DRUG: Bdq, Lzd, Lfx, Z, Dlm (9-12 months)

Sponsor

Harvard Medical School (HMS and HSDM)

Collaborators

[object Object]
[object Object]
[object Object]